Ligand Pharmaceuticals Income Statement

Financials in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	348.2	322.11	295.45	247.67
Revenue Growth (YoY)	17.64%	9.03%	19.29%	-
Cost of Revenue	268.19	248.73	229.61	196.46
Gross Profit	80.01	73.38	65.84	51.21
Selling, General & Admin	42.84	38.55	36.98	30.31
Operating Expenses	51.23	46.61	37.48	54.64
Operating Income	28.78	26.77	28.36	-3.43
Interest Expense	-10.99	-10.79	-11.1	-6.68
Interest & Investment Income	0.64	0.72	0.75	0.03
Currency Exchange Gain (Loss)	-0.38	-0.38	-0.13	0.77
Pretax Income	18.05	16.32	17.88	-9.32
Income Tax Expense	5.59	5.01	5.24	-0.32
Earnings From Continuing Operations	12.46	11.31	12.63	-9
Minority Interest in Earnings	-1.06	-1.39	-1.71	-0.88
Net Income	11.41	9.93	10.92	-9.88
Net Income to Common	11.41	9.93	10.92	-9.88
Net Income Growth	7.59%	-9.14%	-	-
Shares Outstanding (Basic)	2	2	2	2
Shares Outstanding (Diluted)	2	2	2	2
Shares Change (YoY)	10.08%	6.59%	5.15%	-
EPS (Basic)	5.06	4.58	5.41	-4.89
EPS (Diluted)	4.86	4.38	5.14	-4.89
EPS Growth	-2.28%	-14.79%	-	-
Free Cash Flow	45.65	38.11	27.84	13.15
Free Cash Flow Per Share	19.46	16.83	13.11	6.51
Dividend Per Share	2.094	2.094	-	-
Gross Margin	22.98%	22.78%	22.29%	20.67%
Operating Margin	8.27%	8.31%	9.60%	-1.39%
Profit Margin	3.28%	3.08%	3.70%	-3.99%
Free Cash Flow Margin	13.11%	11.83%	9.42%	5.31%
EBITDA	39.98	36.63	37.37	1.75
EBITDA Margin	11.48%	11.37%	12.65%	0.71%
D&A For EBITDA	11.2	9.87	9.01	5.19
EBIT	28.78	26.77	28.36	-3.43
EBIT Margin	8.27%	8.31%	9.60%	-1.39%
Effective Tax Rate	30.96%	30.70%	29.33%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.